0001209191-21-050934.txt : 20210811 0001209191-21-050934.hdr.sgml : 20210811 20210811171415 ACCESSION NUMBER: 0001209191-21-050934 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210809 FILED AS OF DATE: 20210811 DATE AS OF CHANGE: 20210811 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Levin Andrew David CENTRAL INDEX KEY: 0001867539 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40708 FILM NUMBER: 211164558 MAIL ADDRESS: STREET 1: C/O ELIEM THERAPEUTICS, INC. STREET 2: 23515 NE NOVELTY HILL RD, STE B221 #125 CITY: REDMOND STATE: WA ZIP: 98053 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eliem Therapeutics, Inc. CENTRAL INDEX KEY: 0001768446 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832273741 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 23515 NE NOVELTY HILL RD., SUITE B221 #1 CITY: REDMOND STATE: WA ZIP: 98077 BUSINESS PHONE: 16502240857 MAIL ADDRESS: STREET 1: 23515 NE NOVELTY HILL RD., SUITE B221 #1 CITY: REDMOND STATE: WA ZIP: 98077 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-08-09 0 0001768446 Eliem Therapeutics, Inc. ELYM 0001867539 Levin Andrew David C/O ELIEM THERAPEUTICS, INC. 23515 NE NOVELTY HILL RD, STE. B221 #125 REDMOND WA 98053 1 0 0 0 Stock Option (Right to Buy) 12.50 2021-08-09 4 A 0 20000 0.00 A 2031-08-08 Common Stock 20000 20000 D For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/36th of the shares will vest on each monthly anniversary of August 1, 2021. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock. /s/ Alan Hambelton, Attorney-in-Fact 2021-08-11